Amphastar Pharmaceuticals (AMPH) FY2023 results: revenue $644 million, up 29.1% on the year
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $644 million for fiscal 2023, the year ended 31 December 2023, up 29.1% on the year before. Net income was $138 million, up 50.5%, and diluted earnings per share $2.60. The figures are the company's own, from the 10-K it filed with the SEC on 29 February 2024.
Revenue
$644 million
+29.1% on the year
FY2016FY2023
Operating margin
30.6%
21.5% a year earlier
FY2016FY2023
Net income
$138 million
+50.5% on the year
FY2016FY2023
Diluted EPS
$2.60
+49.4% on the year
FY2016FY2023
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2023
FY2022
FY2021
On the year
Last 8 years
Operating cash flow
184
89.2
98.0
+105.8%
Capital expenditure
38.2
24.0
27.5
+58.8%
Free cash flow
145
65.1
70.5
+123.1%
Free cash flow margin
22.6%
13.1%
16.1%
Cash from investing
-649
-32.8
-28.7
Cash from financing
454
-26.4
-37.0
Depreciation and amortisation
25.7
12.6
10.2
+104.3%
Share-based compensation
20.2
17.9
18.7
+13.3%
Buybacks
58.1
39.9
28.9
+45.7%
Diluted shares, weighted
53m
52m
50m
+1.1%
Shares outstanding at period end
48m
48m
48m
-0.1%
Balance sheet
$ million
FY2023
FY2022
FY2021
On the year
Last 8 years
Shareholders' equity
639
529
446
+21.0%
Debt
603
76.6
78.2
+687.0%
Operating lease liabilities
29.7
23.7
24.7
+25.4%
Finance lease liabilities
0.6
0.8
0.4
-22.0%
Other liabilities
240
112
123
+113.9%
Total liabilities and equity
1,513
742
672
+103.9%
Fixed assets
283
238
244
+18.7%
Goodwill
3.2
3.1
3.3
+2.9%
Intangible assets
581
4.9
6.3
+11,641.5%
Investments
127
19.7
10.3
+546.8%
Cash and equivalents
144
156
126
-7.6%
Receivables
115
88.8
78.8
+29.4%
Inventory
106
104
92.8
+2.2%
Other assets
154
127
109
+20.7%
Total assets
1,513
742
672
+103.9%
10-K for the year ended 31 December 2023, filed 29 February 2024: the filing.